Alexander Wu, PhD

Team Leader / Project Manager at Applied StemCell Inc
  • Claim this Profile
Contact Information
us****@****om
(386) 825-5501
Location
San Mateo, California, United States, US

Topline Score

Topline score feature will be out soon.

Bio

Generated by
Topline AI

5.0

/5.0
/ Based on 2 ratings
  • (2)
  • (0)
  • (0)
  • (0)
  • (0)

Filter reviews by:

Wei Francis Qiu, MD,PhD,MBA (邱炜)

I have known Alex for about 10 years and worked closely together in Boston. Alex is an extremely talented scientist with unparalleled critical thinking and passion in medicine. He impressed me the most of his hard working ethics and dedication to group projects. He is a great team player with excellent interpersonal skills to manage project execution to achieve the best outcomes possible. Alex is a widely respected colleague, a good friend of whomever he worked with. His easy-going charisma means a great deal to many. I put Alex in my highest regard, he will be a great asset to any team he will be engaged in.

Xuan Gao, Ph.D.

Alex has an in-depth knowledge in molecular biology and cell biology. He has given lots of valuable suggestions to me and my other colleagues in cloning. He is a great person and a wonderful colleague, and always willing to share his knowledge and spend time to help other people even when himself is busy.

You need to have a working account to view this content.
You need to have a working account to view this content.

Experience

    • United States
    • Biotechnology Research
    • 1 - 100 Employee
    • Team Leader / Project Manager
      • Feb 2011 - Present

      • Managing transgenic service projects including project design, supervising, trouble-shooting and communicating with clients. Significantly improving the gene targeting efficiency and shortening the turnaround time of projects. • In charge of products, service, and development related to the company’s proprietary technology, TARGATT, which is used for site-specific knockin. • Constructed and engineered antibody expression vector, introduced into DHFR-deficient CHO cells (DG44)… Show more • Managing transgenic service projects including project design, supervising, trouble-shooting and communicating with clients. Significantly improving the gene targeting efficiency and shortening the turnaround time of projects. • In charge of products, service, and development related to the company’s proprietary technology, TARGATT, which is used for site-specific knockin. • Constructed and engineered antibody expression vector, introduced into DHFR-deficient CHO cells (DG44), selected high expression clones using high-throughput (HTP) ELISA screening • Actively participating in R & D of stem cell related products and service including the generation of iPS cells by miRNA and a neural stem cell generation. Show less • Managing transgenic service projects including project design, supervising, trouble-shooting and communicating with clients. Significantly improving the gene targeting efficiency and shortening the turnaround time of projects. • In charge of products, service, and development related to the company’s proprietary technology, TARGATT, which is used for site-specific knockin. • Constructed and engineered antibody expression vector, introduced into DHFR-deficient CHO cells (DG44)… Show more • Managing transgenic service projects including project design, supervising, trouble-shooting and communicating with clients. Significantly improving the gene targeting efficiency and shortening the turnaround time of projects. • In charge of products, service, and development related to the company’s proprietary technology, TARGATT, which is used for site-specific knockin. • Constructed and engineered antibody expression vector, introduced into DHFR-deficient CHO cells (DG44), selected high expression clones using high-throughput (HTP) ELISA screening • Actively participating in R & D of stem cell related products and service including the generation of iPS cells by miRNA and a neural stem cell generation. Show less

    • United States
    • Higher Education
    • 700 & Above Employee
    • Research Fellow
      • Sep 2004 - Feb 2011

      • Studied the transcriptional profiling of p63 and its human disease-derived mutants using microarray and Q-PCR analyses, discovered critical downstream targets of p63 in controlling cancer cell invasion and metastasis • Investigated the signaling pathway regulating p63 protein in cancer development, discovered that GSK3 pathway is a major regulator of p63 expression • Studied cell response to Nutlin 3 (an anti-cancer drug in clinical trials) treatment and… Show more • Studied the transcriptional profiling of p63 and its human disease-derived mutants using microarray and Q-PCR analyses, discovered critical downstream targets of p63 in controlling cancer cell invasion and metastasis • Investigated the signaling pathway regulating p63 protein in cancer development, discovered that GSK3 pathway is a major regulator of p63 expression • Studied cell response to Nutlin 3 (an anti-cancer drug in clinical trials) treatment and discovered that the status of Rb protein determines cell fate in response to Nutlin3. • Investigated drug combinations in cancer therapy revealing that pretreatment of rapamycin sensitizes cancer cells to doxorubicin. • Collaborated with GlaxoSmithKline on the oncogenic study of GAM1, an adenoviral protein accessory to vaccine production and gene therapy. • Investigated transcriptional regulation of genes critical to replication senescence, screened proteins binding to a specific DNA element using the yeast one-hybrid system. Show less • Studied the transcriptional profiling of p63 and its human disease-derived mutants using microarray and Q-PCR analyses, discovered critical downstream targets of p63 in controlling cancer cell invasion and metastasis • Investigated the signaling pathway regulating p63 protein in cancer development, discovered that GSK3 pathway is a major regulator of p63 expression • Studied cell response to Nutlin 3 (an anti-cancer drug in clinical trials) treatment and… Show more • Studied the transcriptional profiling of p63 and its human disease-derived mutants using microarray and Q-PCR analyses, discovered critical downstream targets of p63 in controlling cancer cell invasion and metastasis • Investigated the signaling pathway regulating p63 protein in cancer development, discovered that GSK3 pathway is a major regulator of p63 expression • Studied cell response to Nutlin 3 (an anti-cancer drug in clinical trials) treatment and discovered that the status of Rb protein determines cell fate in response to Nutlin3. • Investigated drug combinations in cancer therapy revealing that pretreatment of rapamycin sensitizes cancer cells to doxorubicin. • Collaborated with GlaxoSmithKline on the oncogenic study of GAM1, an adenoviral protein accessory to vaccine production and gene therapy. • Investigated transcriptional regulation of genes critical to replication senescence, screened proteins binding to a specific DNA element using the yeast one-hybrid system. Show less

Education

  • Boston University School of Medicine
    Ph.D., Biochemistry / Oncology
    2004 - 2010
  • Peking University
    M.S., Geriatrics
    2001 - 2004
  • Peking University
    M.D., Medicine
    1996 - 2001

Community

You need to have a working account to view this content. Click here to join now